1. Home
  2. MIST vs SQNS Comparison

MIST vs SQNS Comparison

Compare MIST & SQNS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MIST
  • SQNS
  • Stock Information
  • Founded
  • MIST 2003
  • SQNS 2003
  • Country
  • MIST Canada
  • SQNS France
  • Employees
  • MIST N/A
  • SQNS N/A
  • Industry
  • MIST Biotechnology: Pharmaceutical Preparations
  • SQNS Semiconductors
  • Sector
  • MIST Health Care
  • SQNS Technology
  • Exchange
  • MIST Nasdaq
  • SQNS Nasdaq
  • Market Cap
  • MIST 81.5M
  • SQNS 70.9M
  • IPO Year
  • MIST N/A
  • SQNS 2011
  • Fundamental
  • Price
  • MIST $1.80
  • SQNS $2.68
  • Analyst Decision
  • MIST Strong Buy
  • SQNS Strong Buy
  • Analyst Count
  • MIST 3
  • SQNS 1
  • Target Price
  • MIST $13.00
  • SQNS $7.50
  • AVG Volume (30 Days)
  • MIST 510.8K
  • SQNS 136.5K
  • Earning Date
  • MIST 11-12-2024
  • SQNS 11-05-2024
  • Dividend Yield
  • MIST N/A
  • SQNS N/A
  • EPS Growth
  • MIST N/A
  • SQNS N/A
  • EPS
  • MIST N/A
  • SQNS 1.65
  • Revenue
  • MIST N/A
  • SQNS $30,555,000.00
  • Revenue This Year
  • MIST N/A
  • SQNS $10.14
  • Revenue Next Year
  • MIST N/A
  • SQNS $8.54
  • P/E Ratio
  • MIST N/A
  • SQNS $1.61
  • Revenue Growth
  • MIST N/A
  • SQNS N/A
  • 52 Week Low
  • MIST $1.12
  • SQNS $0.85
  • 52 Week High
  • MIST $3.52
  • SQNS $7.43
  • Technical
  • Relative Strength Index (RSI)
  • MIST 68.42
  • SQNS 55.52
  • Support Level
  • MIST $1.75
  • SQNS $2.63
  • Resistance Level
  • MIST $2.09
  • SQNS $2.82
  • Average True Range (ATR)
  • MIST 0.15
  • SQNS 0.17
  • MACD
  • MIST 0.04
  • SQNS 0.02
  • Stochastic Oscillator
  • MIST 62.86
  • SQNS 61.64

About MIST Milestone Pharmaceuticals Inc.

Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular indications. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to terminate episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).

About SQNS Sequans Communications S.A.

Sequans Communications SA is a designer, developer, and supplier of cellular semiconductor solutions for broadband Internet of Things (IoT) markets. Its solutions incorporate baseband processor and radio frequency, transceiver integrated circuits, along with its proprietary signal processing techniques, algorithms, and software stacks. The company's solutions serve as the core wireless broadband communications platform in devices, including smartphones, USB dongles, portable routers, laptops, netbooks, tablets, and other consumer multimedia and industrial devices. Its geographical segments are Taiwan, Korea, China (including Hong Kong), the Rest of Asia, the United States and the Rest of the world.

Share on Social Networks: